Home › Funds › PSP Research LLC › PTCT

PSP Research LLC position in PTCT

PTC THERAPEUTICS INC · Health Care

PSP Research LLC reported holding 6,000 shares of PTCT (PTC THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$489K, representing 0.26% of its reported portfolio and ranking #21 among its reported holdings. PSP Research LLC has disclosed PTCT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)6.00K sh
Reported value held$489.42K
Portfolio Weight0.26%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's PTCT position evolved

PSP Research LLC first disclosed a stake in PTCT in Q4 2025 at 7,046 shares (US$535K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 6,000 shares valued at US$489K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 7.05K $535.21K New
Q1 2026 6.00K $408.78K Reduce
Q2 2026 6.00K $489.42K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTCT and 13F data

PTCT (PTC THERAPEUTICS INC) is a Health Care company. 55 other funds we track also report a position in PTCT — the largest reported positions include RTW INVESTMENTS, LP (US$631.9M), TORONTO DOMINION BANK (US$176.7M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$159.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTCT

All PTCT fund holders →